{"product_id":"rare-ansoff-analysis","title":"(RARE) Ultragenyx Pharmaceutical Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Ultragenyx Pharmaceutical Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to help you evaluate strategic and investment choices; the page includes a real preview\/sample of the analysis so you can judge style and substance before buying—purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrysvita uptake in X-linked hypophosphatemia and tumor-induced osteomalacia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCrysvita is already approved for X-linked hypophosphatemia and tumor-induced osteomalacia, so the market penetration play is to push deeper use in the existing treated pool. Ultragenyx said Crysvita remained a core revenue driver in 2025, helping support share gains in these rare-disease markets. That matters because the addressable base is small, so even modest gains in diagnosis, starts, and persistence can lift revenue fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMepsevii adoption in mucopolysaccharidosis VII\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMepsevii is the only approved enzyme replacement therapy for mucopolysaccharidosis VII, so Ultragenyx’s market penetration play is about converting more of the very small diagnosed pool, not expanding the label. MPS VII is ultra-rare, with incidence often cited at under 1 in 1,000,000 births, which makes specialty-center referral and newborn\/clinical diagnosis the main growth lever. The upside comes from Ultragenyx’s established ultra-rare disease channel, where even a few more treated patients can move revenue meaningfully.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDojolvi utilization in long-chain fatty acid oxidation disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDojolvi is an in-market expansion play for Ultragenyx Pharmaceutical Inc. in long-chain fatty acid oxidation disorders, pushing deeper use in already eligible patients rather than chasing a new launch. Ultragenyx said Dojolvi generated about $140 million in annual net product sales in 2025, showing the brand already has a live base to grow from. \u003c\/p\u003e\n\u003cp\u003eThat matters because the market is rare but not closed: LC-FAOD care is concentrated in specialist centers, so each added diagnosis and each switch to treatment can lift penetration fast. The upside comes from better screening, tighter referral paths, and stronger use of an approved therapy in current markets. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEvkeeza access in homozygous familial hypercholesterolemia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvkeeza expands access in the existing homozygous familial hypercholesterolemia population, where HoFH is ultra-rare at roughly 1 in 250,000 to 1 in 360,000 people. For Ultragenyx Pharmaceutical Inc., market penetration means driving uptake in the same approved rare cardiovascular segment, not chasing a new disease area.\u003c\/p\u003e\n\u003cp\u003eThe key lever is faster diagnosis, specialist referral, and payer coverage, because even small gains matter in a tiny patient pool. Evkeeza is already a treatment option for patients with HoFH aged 5 years and older, so growth depends on deeper use inside current eligible patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: approved HoFH segment only\u003c\/li\u003e\n\u003cli\u003eDriver: access, reimbursement, referral\u003c\/li\u003e\n\u003cli\u003eGoal: raise use per eligible patient\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-product commercialization across North America, Europe, and other international markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx Pharmaceutical Inc. can push multiple marketed products into the same North American, European, and other international channels, so each launch or label expansion can lift share in territories where it already sells. In 2025, that base included Crysvita, Dojolvi, and Evkeeza, giving the Company more than one lever for commercial execution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses existing regional sales footprints\u003c\/li\u003e\n\u003cli\u003eSells several products into the same markets\u003c\/li\u003e\n\u003cli\u003eSupports share gains without new geography buildout\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx Growth Hinges on Deeper Penetration, Not Bigger Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration for Ultragenyx Pharmaceutical Inc. is about selling more into already approved rare-disease pools, led by Crysvita, Dojolvi, Mepsevii, and Evkeeza. In 2025, Dojolvi delivered about $140 million in net product sales, showing how deeper diagnosis, referral, and persistence can lift revenue fast. The main limit is pool size, so growth depends on access, not new markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003ePenetration lever\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrysvita\u003c\/td\u003e\n\u003ctd\u003eCore revenue driver\u003c\/td\u003e\n\u003ctd\u003eMore starts, persistence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDojolvi\u003c\/td\u003e\n\u003ctd\u003eAbout $140M sales\u003c\/td\u003e\n\u003ctd\u003eMore diagnosis, referrals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMepsevii\u003c\/td\u003e\n\u003ctd\u003eUltra-rare pool\u003c\/td\u003e\n\u003ctd\u003eConvert diagnosed patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Ultragenyx Pharmaceutical Inc.’s growth strategy across products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ultragenyx Pharmaceutical Inc. Ansoff Matrix to quickly pinpoint growth options and simplify strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of Ultragenyx sources to validate Ansoff Matrix growth paths and speed due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrysvita geographic expansion beyond the core U.S. base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCrysvita is already sold in multiple markets, so Ultragenyx Pharmaceutical Inc. can grow by adding country-level access in North America, Europe, and other regions without changing the product. That is classic market development: same drug, wider reach. In the latest reported period, Ultragenyx said Crysvita revenue remained its largest product line, showing the franchise already has scale to support new launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMepsevii reach across additional international rare-disease centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMepsevii, Ultragenyx Pharmaceutical Inc.'s vestronidase alfa for MPS VII, is a clear market-development play: an existing product pushed into more countries and rare-disease centers beyond its original launch base. Ultragenyx reported 2025 net product revenue of about $597 million, showing the commercial base that can support this wider reach. More center access can lift diagnosis, infusion starts, and long-tail sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDojolvi expansion into broader ex-U.S. patient access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDojolvi targets long-chain fatty acid oxidation disorders, a rare disease set seen in roughly 1 in 50,000 to 1 in 100,000 births, so ex-U.S. expansion can grow Ultragenyx Pharmaceutical Inc.'s reach without changing the therapy. This is classic market development: same product, new geographies, more patients. Because the patient pool is small but high-need, even modest access gains can add meaningful orphan-drug revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEvkeeza rollout through international rare cardiovascular channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEvkeeza is a marketed biologic that fits Ultragenyx Pharmaceutical Inc.'s market-development move: take an existing HoFH therapy into more countries and rare-cardiovascular channels. HoFH is ultra-rare, at roughly 1 in 250,000 to 1 in 1,000,000 people, so each new territory can add meaningful patient access without a new asset.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting biologic, new geographies\u003c\/li\u003e\n\u003cli\u003eTargets ultra-rare HoFH patients\u003c\/li\u003e\n\u003cli\u003eChannel expansion, not new R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-supported regional expansion in Europe and other international markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx uses partner-backed expansion to move existing rare-disease products into Europe and other international markets without building every country launch alone. Its agreements with Kyowa Kirin, Bayer Healthcare, Daiichi Sankyo, and others extend commercial reach beyond the U.S. and support faster local access where partners already have payer and regulatory ties.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e4 named partners widen geographic reach.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLicensing helps enter new countries faster.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eRegional partners lower launch burden.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx Expands Rare-Disease Reach Without New Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx Pharmaceutical Inc. can grow by taking Crysvita, Mepsevii, Dojolvi, and Evkeeza into more countries and rare-disease centers without changing the drugs. That is market development: same assets, wider reach. Ultragenyx Pharmaceutical Inc. reported about $597 million in 2025 net product revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e$597M\u003c\/td\u003e\n\u003ctd\u003eNet product revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003ePartner links cited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSame drugs\u003c\/td\u003e\n\u003ctd\u003eNew geographies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eUltragenyx Pharmaceutical Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDTX401 for glycogen storage disease type Ia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDTX401 is Ultragenyx Pharmaceutical Inc.'s AAV8 gene therapy for glycogen storage disease type Ia, a rare disorder seen in roughly 1 in 100,000 births. It is a new product candidate for a defined ultra-rare metabolic market, so it fits product development rather than current sales. As a future launch asset, it could expand Ultragenyx's reach beyond its marketed portfolio if late-stage data support approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDTX301 for ornithine transcarbamylase deficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDTX301 is Ultragenyx Pharmaceutical Inc.s AAV8 gene therapy for ornithine transcarbamylase deficiency, a rare X-linked urea-cycle disorder seen in about 1 in 14,000 to 1 in 77,000 births. In the Ansoff Matrix, it fits product development: a new therapy for the companys rare-disease base, broadening the portfolio beyond existing metabolic treatments. This adds a distinct, high-value option in a high-unmet-need market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUX143 for osteogenesis imperfecta\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUX143 is Ultragenyx Pharmaceutical Inc.'s human monoclonal antibody in development for osteogenesis imperfecta, a disease affecting about 1 in 15,000 to 20,000 births. It expands the pipeline beyond marketed drugs like Crysvita and Dojolvi, while staying inside the company’s ultra-rare disease focus. That makes it clear product creation in Ansoff terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGTX-102 for Angelman syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGTX-102 is Ultragenyx Pharmaceutical Inc.'s antisense oligonucleotide for Angelman syndrome, a rare neurogenetic disorder seen in about 1 in 15,000 births. It adds a new modality to the pipeline, moving beyond the Company's marketed rare-disease set and into a high-unmet-need CNS market.\u003c\/p\u003e\n\u003cp\u003eIn Ansoff terms, this is product development: a new therapy for a new biology-driven use case, not an extension of current sales. If successful, it could widen Ultragenyx Pharmaceutical Inc.'s addressable patient base while also raising R\u0026amp;D and clinical risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew modality: antisense oligonucleotide\u003c\/li\u003e\n\u003cli\u003eTargets Angelman syndrome, not marketed products\u003c\/li\u003e\n\u003cli\u003eRare disease prevalence: ~1 in 15,000 births\u003c\/li\u003e\n\u003cli\u003eSupports pipeline expansion, not market penetration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUX701 and UX053 for Wilson disease and glycogen storage disease type III\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUX701 for Wilson disease and UX053 for glycogen storage disease type III are new pipeline assets in Ultragenyx Pharmaceutical Inc.'s product development bucket, so this is market development into two rare-disease niches. Wilson disease affects about 1 in 30,000 people, while GSD III is also ultra-rare, so each program targets a small but high-need patient base and broadens the future slate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo distinct rare-disease programs\u003c\/li\u003e\n\u003cli\u003eExtends Ultragenyx Pharmaceutical Inc.'s slate\u003c\/li\u003e\n\u003cli\u003eFits product development strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx Bets on Rare-Disease Pipeline Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx Pharmaceutical Inc. uses product development by adding new rare-disease therapies to its base, not by pushing current drugs into new markets. DTX401, DTX301, UX143, and GTX-102 all target ultra-rare, high-unmet-need diseases and could expand the pipeline if late-stage data and approvals land. In 2025, Ultragenyx Pharmaceutical Inc. reported total revenue of about $609 million, showing the company still funds a deep R\u0026amp;D slate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTX401\u003c\/td\u003e\n\u003ctd\u003eGSD Ia\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGTX-102\u003c\/td\u003e\n\u003ctd\u003eAngelman syndrome\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene therapy entry into glycogen storage disease type Ia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDTX401 moves Ultragenyx Pharmaceutical Inc. into AAV8 gene therapy for glycogen storage disease type Ia, a rare disorder affecting about 1 in 100,000 births. It is a new product in a new disease market, so this is clear diversification under the Ansoff Matrix. It also broadens Ultragenyx beyond its marketed biologics base and adds one more late-stage growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene therapy entry into ornithine transcarbamylase deficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDTX301 uses AAV8 gene therapy for ornithine transcarbamylase deficiency, a rare urea-cycle disorder that affects about 1 in 14,000 live births. \u003c\/p\u003e\n\u003cp\u003eFor Ultragenyx Pharmaceutical Inc., this moves beyond its core rare-disease base into a separate metabolic market. \u003c\/p\u003e\n\u003cp\u003eThat means one new product and one new franchise area, with upside if late-stage data keep supporting efficacy and safety. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBone-disorder expansion through osteogenesis imperfecta\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUX143, Ultragenyx Pharmaceutical Inc.'s setrusumab for osteogenesis imperfecta, moves the company into a new bone-disease market beyond its approved rare-disease products. OI is a very small niche, affecting about 1 in 15,000 to 20,000 births, so the upside is portfolio breadth, not scale. If approved, it would widen Ultragenyx Pharmaceutical Inc.'s rare-disease mix and reduce dependence on its current franchises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeurogenetic diversification through Angelman syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGTX-102, Ultragenyx Pharmaceutical Inc.'s antisense oligonucleotide for Angelman syndrome, pushes the company into a new neurogenetic market with a different modality. Angelman syndrome affects about 1 in 12,000 to 20,000 births, so this adds disease-area diversity and lowers reliance on metabolic rare-disease assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew neurogenetic indication\u003c\/li\u003e\n\u003cli\u003eAntisense oligonucleotide modality\u003c\/li\u003e\n\u003cli\u003eBroader pipeline and tech mix\u003c\/li\u003e\n\u003cli\u003eRare-disease market expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHepatic and metabolic diversification through Wilson disease and GSD III\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUX701 for Wilson disease and UX053 for glycogen storage disease type III widen Ultragenyx Pharmaceutical Inc.'s rare-disease reach beyond its current commercial base, which includes Crysvita, Dojolvi, and Mepsevii. Wilson disease affects about 1 in 30,000 to 1 in 40,000 people, while GSD III is similarly ultra-rare, so each program adds a distinct, high-unmet-need market. Together, they deepen hepatic and metabolic diversification across multiple orphan indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUX701 expands into Wilson disease.\u003c\/li\u003e\n\u003cli\u003eUX053 expands into GSD III.\u003c\/li\u003e\n\u003cli\u003eBoth reduce reliance on current products.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx Expands Rare-Disease Reach With New Modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUltragenyx Pharmaceutical Inc. is using diversification to add new rare-disease markets with new modalities, not just new drugs. DTX401 and DTX301 expand into AAV8 gene therapy, UX143 adds bone disease, and GTX-102 brings in antisense therapy.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTX401\u003c\/td\u003e\n\u003ctd\u003eGSD Ia\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTX301\u003c\/td\u003e\n\u003ctd\u003eOTC deficiency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUX143\u003c\/td\u003e\n\u003ctd\u003eOsteogenesis imperfecta\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGTX-102\u003c\/td\u003e\n\u003ctd\u003eAngelman syndrome\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234853593353,"sku":"rare-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/rare-ansoff-matrix.webp?v=1785729733","url":"https:\/\/dcfanalyst.com\/products\/rare-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}